[Medication for ending tobacco dependency. Current state].
F
F
Camarelles Guillem
D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use; D016642:Bupropion / Q000008:administration & dosage / Q000627:therapeutic use; D063387:Cannabinoid Receptor Antagonists; D006801:Humans; D009538:Nicotine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D011978:Receptors, Nicotinic / Q000187:drug effects; D000077285:Rimonabant; D016540:Smoking Cessation / Q000379:methods / Q000523:psychology; D013997:Time Factors; D014029:Tobacco Use Disorder / Q000188:drug therapy* / Q000523:psychology; D000068580:Varenicline
D018687:Antidepressive Agents, Second-Generation; D001552:Benzazepines; D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D011810:Quinoxalines; D011978:Receptors, Nicotinic; D016642:Bupropion; D009538:Nicotine; D000077285:Rimonabant; D000068580:Varenicline